Nymox Pharmaceutical Corporation
NYMXF
$0.0751
-$0.0049-6.13%
OTC PK
| 12/31/2024 | 09/30/2024 | 12/31/2023 | 12/31/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -94.20% | -59.77% | 390.47% | 390.47% | -47.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -83.75% | -35.60% | 387.66% | 387.66% | -38.06% |
| Operating Income | 83.75% | 35.60% | -387.66% | -387.66% | 38.06% |
| Income Before Tax | 83.86% | 30.89% | -296.64% | -296.64% | -182.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 83.86% | 30.89% | -296.64% | -296.64% | -182.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 83.86% | 30.89% | -296.64% | -296.64% | -182.84% |
| EBIT | 83.75% | 35.60% | -387.66% | -387.66% | 38.06% |
| EBITDA | 83.74% | 35.44% | -386.97% | -386.97% | 33.54% |
| EPS Basic | 84.28% | 31.25% | -288.59% | -288.59% | -182.43% |
| Normalized Basic EPS | 82.83% | 31.43% | -256.99% | -256.99% | -181.72% |
| EPS Diluted | 84.28% | 10.71% | -288.59% | -288.59% | -222.00% |
| Normalized Diluted EPS | 82.83% | 31.43% | -256.99% | -256.99% | -196.20% |
| Average Basic Shares Outstanding | 2.48% | 1.50% | 2.26% | 2.26% | 0.93% |
| Average Diluted Shares Outstanding | 2.48% | 1.50% | 2.26% | 2.26% | -13.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |